Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Drospirenone/ethinylestradiol low-dose - Bayer HealthCare Pharmaceuticals

Drug Profile

Drospirenone/ethinylestradiol low-dose - Bayer HealthCare Pharmaceuticals

Alternative Names: BAY86-5300; BAY86-5300-YAZ-Flex; Dihydrospirorenone/ethinylestradiol low-dose; Drospirenone/ethinyl estradiol; EE20/Drospirenone; EE20/DRSP; Ethinylestradiol-Drospirenone 24+4; Flexyess; SH-T-00186D; Yasmin® 20; Yasminelle; Yaz; Yaz 24+4; Yaz Extended Cycle; YAZ Extended Regimen; Yaz Flex; Yvidually

Latest Information Update: 17 Jan 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals; Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals; Bayer HealthCare Pharmaceuticals Inc.
  • Class Alkylated estrogenic steroids; Androstenes; Norpregnatrienes; Oral contraceptives; Progesterone congeners; Small molecules
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Acne; Dysmenorrhoea; Pregnancy; Premenstrual dysphoric disorder; Premenstrual syndrome
  • No development reported Endometriosis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 17 Jan 2018 No development reported - Phase-III for Acne in China (PO)
  • 17 Jan 2018 No development reported - Phase-III for Endometriosis in Japan (PO)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top